Open-Label, Non-Randomized Study Investigating the Excretion Balance, Pharmacokinetics, and Metabolism of a Single Oral Dose of [14C]-Labeled RO7269162 in Healthy Male Participants
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs RO-7269162 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Roche
- 22 Jan 2025 Planned End Date changed from 23 Feb 2025 to 25 Feb 2025.
- 22 Jan 2025 Planned primary completion date changed from 7 Jan 2025 to 25 Feb 2025.
- 22 Jan 2025 Status changed from not yet recruiting to recruiting.